---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-23-000052"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2023-09-18T23:59:59+00:00"
generated_at: "2026-06-10T14:34:49.632298+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio Chairman James Topper resigns; John Orwin named Chairman

## Summary
- James Topper resigned as Class II director and Chairman effective Sept 15, 2023; no disagreement with company.
- Topper will serve as advisor to the Board through Q1 2024 under an Advisory Agreement.
- John Orwin appointed Class II director and Chairman on Sept 15, 2023.
- Orwin received initial equity grants: option for 3,311 shares (vesting monthly to Jan 2024) and 2,035 RSUs (vest at 2024 annual meeting).
- Orwin also granted option for 10,600 shares (3-year monthly vest) and 3,900 RSUs (3-year annual vest).

## SEC filing metadata
- accession: 0001370053-23-000052
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2023-09-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000052/0001370053-23-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000052/anab-20230914.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-23-000052
- JSON: https://secwatch.observer/filing/0001370053-23-000052.json
- Plain text: https://secwatch.observer/filing/0001370053-23-000052.txt

## Key facts
- Executive change
  John Orwin was appointed as Chairman at ANAPTYSBIO, INC.
  - Action: appointed
  - Role: Chairman
  source text: On September 15, 2023, the Board appointed John Orwin as a Class II director, a member of the Nominating and Corporate Governance Committee and Chairman of the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000052/0001370053-23-000052-index.htm
- Executive change
  James N. Topper resigned as Chairman at ANAPTYSBIO, INC.
  - Action: resigned
  - Role: Chairman
  source text: On September 14, 2023, James N. Topper, M.D., Ph.D., advised the Board of Directors (the “ Board ”) of AnaptysBio, Inc. (the “ Company ”) that he would resign as a Class II director and as Chairman of the Board, effective on September 15, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000052/0001370053-23-000052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.